Clinical trials: Covid19 Vaccination
Covid-19
Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020
Experimental Use of Convalescent Plasma of Passive Immunisation In Current COVID-19 Pandemic in Pakistan in 2020 Rationale \& Objective: This study would help to gather real-life setting clinical data in local population…
- Trial name
- NCT04352751
- Testing
- convalescent plasma
- Where
- Pakistan
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Hilton Pharma
SARS-CoV2 Infection
Heterologous SARS-CoV-2 Vaccination With ChAdOx-1 and BNT162b2
This study will analyze the safety and efficacy of the heterologous vaccination with Vaxzevria followed by Comirnaty. As a control individuals will be vaccinated with Comirnaty or Vaxzevria twice.
- Trial name
- HeVacc (NCT04907331)
- Testing
- Vaxzevria, Comirnaty
- Where
- Austria
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Medical University Innsbruck
COVID-19 Vaccination
Determinants of Obtaining Covid Vaccination Among Health Care Workers
Despite the global preventive efforts (physical distancing, face, mask, travel constraints, and quarantine) to contain the infection, COVID-19 is continuing with its devastating consequences on health, life, and economics.
- Trial name
- NCT04924894
- Testing
- no intervention
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Assiut University
Vaccination; Infection, Covid19
Risk of COVID-19 Infection After Vaccination
The purpose of this observational nationwide study is to evaluate the effects of three different COVID-19 vaccines for the outcome of different severities of incident COVID infection.
- Trial name
- NCT04848441
- Testing
- The COVID-19 vaccines BNT162b2, mRNA-1273 and ChAdOx1
- Volunteers
- 2,000,000 people
- Sponsor
- Umeå University
COVID-19
Homologous vs Heterologous Third Vaccination in Kidney Transplant Recipients Kidney Transplant Recipients
Randomized-controlled trial comparing homologous (mRNA vaccine) vs. heterologous (vector vaccine) for third SARS-CoV-2 vaccine dose in kidney transplant recipients not responding to initial prime-boost vaccination with an mRNA…
- Trial name
- BOOST_TX (NCT05324319)
- Testing
- Ad26COVS1, ChAdOx1 SARS2 Vaccine, BNT162B2
- Where
- Austria
- Volunteers
- 200 people
- Sponsor
- Medical University of Vienna
COVID-19 Stress Syndrome, COVID-19 Vaccine Adverse Reaction
COVID-19 Vaccination Detoxification in LDL-C
The study hypothesizes that SARS-CoV-2 vaccination poisoning hibernates in human host in Low Density Lipoprotein Cholesterol (LDL-C). The clinical trial is a follow-up from the intervention trial with NCT number NCT05711810.
- Conditions
- COVID-19 Stress Syndrome, COVID-19 Vaccine Adverse Reaction, COVID-19-Associated Thromboembolism, COVID-19 Post-Intensive Care Syndrome
- Trial name
- NCT05839236
- Testing
- Atorvastatin Calcium Tablets
- Where
- China
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Yang I. Pachankis
COVID-19 Infection, COVID-19 VACCINE
Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine
This prospective, multi-center, randomized, observer-blind Phase 2 study. A total of 1320 participants will be divided into 2 groups (660 each) receiving either full dose or half dose of either AZ or PF.
- Trial name
- NCT05049226
- Testing
- AstraZeneca ChAdOx1 AZD1222 vaccine (AZ) full dose, Pfizer/BioNTech BNT162b2 vaccine (PF) full dose, AstraZeneca ChAdOx1 AZD1222 vaccine (AZ) half dose
- Where
- 7 sites in Thailand
- Volunteers
- 1,250 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Spinal Cord Injuries, Traumatic Spinal Cord Injury
SCIVAX: Biomarkers of Immune Dysfunction and Vaccine Responsiveness in Chronic SCI
The purpose of this observational research study is to better understand immune responses to vaccines against viruses (influenza or SARS-CoV2).
- Conditions
- Spinal Cord Injuries, Traumatic Spinal Cord Injury, Healthy Controls, Flu Vaccine
- Trial name
- SCIVAX (NCT05869968)
- Where
- United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Vaccine Preventable Disease
COVID-19 Antibody Levels After Vaccines
This study will measure the levels of nasal mucosal Immunoglobulin A (IgA) and blood serum IgA up to one year after COVID vaccination, as well as examining what factors might affect antibody levels in the nose.
- Trial name
- NCT04944134
- Testing
- COVID-19 Vaccination
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- University of North Carolina, Chapel Hill
Vaccination Refusal
Increasing COVID-19 Vaccine Uptake in Developing Countries (Bihar)
Working with governments in Bihar, India, we will evaluate a number of mechanisms to increase vaccine uptake. These include household vaccination visits instead of community vaccination clinic.monetary and non-monetary…
- Trial name
- NCT05225064
- Testing
- Incentives to be vaccinated, Mask, Encouragement to wear a mask
- Where
- India
- Volunteers
- 114,512 people, healthy volunteers welcome
- Sponsor
- Yale University
SARS CoV 2 Infection
A Phase IIb/III Clinical Trial to Assess Safety and Immunogenicity of a COVID-19 Vaccine Booster Dose in Immunosupressed Adults.
A phase IIb/III, open label, single arm, multi-centre, trial to assess the immunogenicity and safety of an additional dose vaccination with a recombinant protein RBD fusion heterodimer candidate (PHH-1V) against SARS-CoV-2, in…
- Trial name
- NCT05303402
- Testing
- PHH-1V
- Where
- 6 sites in Spain, Turkey (Türkiye)
- Volunteers
- 241 people
- Sponsor
- Hipra Scientific, S.L.U
Myocarditis
Incidence, Patient Characteristics and Outcome of Myocarditis After COVID-19 mRNA Vaccine
This study evaluates the incidence, patient characteristics and outcome of myocarditis after the COVID-19 mRNA vaccination in healthcare professionals.
- Trial name
- MACIS (NCT05438472)
- Testing
- data collection in healthcare professionals with COVID-19 mRNA vaccine booster
- Where
- Switzerland
- Volunteers
- 835 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
COVID-19 Pneumonia, Coronavirus Infections
Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above
This is randomized, blinded and controlled design. Among the randomly selected subjects who have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell), based on a step-wise approach, the subjects will receive…
- Trial name
- NCT05069129
- Testing
- Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08), Inactivated COVID-19 vaccine (Vero cells), 3 doses Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)
- Where
- United Arab Emirates
- Volunteers
- 1,848 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
Covid-19 Vaccination
The Effect of Covid-19 Vaccination in Patients Undergoing IVF
Since emerging in the last months of 2019, over 127 000 000 individuals have suffered severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection, and the documented death toll from coronavirus disease 2019 (COVID-19)…
- Trial name
- Covid-19 (NCT05063942)
- Volunteers
- 712 people
- Sponsor
- Shanghai First Maternity and Infant Hospital
Influenza, COVID-19
Text4Vax: Text Message Reminders for Pediatric COVID-19 and Influenza Vaccines 2024-25 Season
This multi-site study assesses the impact of text message reminders on the receipt of COVID-19 and influenza text message reminders takes place primarily in practices from the American Academy of Pediatrics (AAP) Pediatric…
- Conditions
- Influenza, COVID-19, Vaccination Hesitancy
- Trial name
- NCT06603090
- Testing
- Text message influenza vaccine reminders, Text message COVID-19 vaccine reminders, Text message influenza and COVID-19 vaccine reminders
- Where
- 4 sites in United States
- Volunteers
- 66,147 people
- Sponsor
- Columbia University
COVID-19
Message Encouraging Vaccination in Preparation for the Holidays
This experiment is part of a megastudy with a total of ten experimental conditions and a holdout control condition to which patients will be randomly assigned.
- Trial name
- NCT05612360
- Testing
- COVID Booster text messages
- Where
- United States
- Volunteers
- 520,000 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Ebola Virus Disease, COVID-19
Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster Doses
Concurrent vaccination scheduling for key target populations in Rwanda, such as healthcare workers, may confer significant advantages in the provision of vaccine coverage to several infectious diseases.
- Trial name
- NCT06587503
- Testing
- BioNTech - Pfizer COVID-19 vaccine, 1mL saline solution, rVSV∆G-ZEBOV-GP
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of Birmingham
COVID-19
Intradermal COVID-19 Vaccination in the Immunocompromised
COVID-19 is an infectious disease caused by SARS-CoV-2 virus, causing millions of deaths around the globe since the beginning of the pandemic.
- Trial name
- NCT05736913
- Testing
- ID BNT162b2 vaccine, IM BNT162b2 vaccine
- Where
- Hong Kong
- Volunteers
- 130 people
- Sponsor
- The University of Hong Kong
COVID-19, Vaccine Reaction
Immunogenicity and Reactogenicity Following a Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNtech) and Two Adjuvanted Sub-unit Vaccines (SP/GSK) Administered in Adults Who Received 2 Doses of Pfizer-BioNTech mRNA Vaccine as a Primary Vaccination
The vaccination campaign in France began in early 2021 and was declared mandatory for all French people in July 2021. The efficacy of COVID-19 vaccines has since been widely demonstrated, as well as their safety, and now 60% of…
- Trial name
- COVIBOOST (NCT05124171)
- Testing
- BNT162b2, CoV2 preS dTM adjuvanted vaccine (D614), Sanofi/GSK, CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK
- Where
- France
- Volunteers
- 247 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Myocardial Injury, Myocarditis
Myocardial Injury and Outcomes Following COVID-19 Vaccination (MYOVAX Study)
The study will focus on cardiac blood and imaging biomarkers to facilitate early recognition of patients at risk for myocardial injury after COVID-19 vaccination.
- Conditions
- Myocardial Injury, Myocarditis, COVID-19 Vaccination, SARS-CoV-2
- Trial name
- MYOVAX (NCT04967807)
- Testing
- Cardiac PET/MRI, Blood Biomarkers
- Where
- Canada
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto